King v. Burwell Ruling Clears A Path For “Cures,” Avoids Disrupting ACA
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry didn’t have as much at stake in the second major Supreme Court ruling on the Affordable Care Act – but should still be celebrating the decision to upheld the Administration’s approach to exchanges.
You may also be interested in...
Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.